Lenvatinib Can Overcome Immune Resistance in Head and Neck Cancer and Achieve Durable Remission
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Lenvatinib Can Overcome Immune Resistance in Head and Neck Cancer and Achieve Durable Remission ; day:09 ; month:03 ; year:2023
South Asian journal of cancer ; (09.03.2023)
- Contributor
-
Suri, Oshin
Gupta, Vineet Govinda
- DOI
-
10.1055/s-0043-1762939
- URN
-
urn:nbn:de:101:1-2023042714532879619201
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Suri, Oshin
- Gupta, Vineet Govinda
Other Objects (12)
Time to achieve remission determines time to be in remission
Exploiting antitumor immunity to overcome relapse and improve remission duration
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Durable clinical remission of a skull metastasis under intralesional Viscum album extract therapy : : case report
Lenvatinib beim Radiojod-refraktären differenzierten Schilddrüsenkarzinom
Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Optimal monetary policy with durable and non-durable goods
Lenvatinib beim inoperablen oder fortgeschrittenen hepatozellulären Karzinom
Lenvatinib (Schilddrüsenkarzinom) : Nutzenbewertung gemäß § 35a SGB V
Time to achieve remission determines time to be in remission
Exploiting antitumor immunity to overcome relapse and improve remission duration
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Durable clinical remission of a skull metastasis under intralesional Viscum album extract therapy : : case report
Lenvatinib beim Radiojod-refraktären differenzierten Schilddrüsenkarzinom
Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Optimal monetary policy with durable and non-durable goods
Lenvatinib beim inoperablen oder fortgeschrittenen hepatozellulären Karzinom
Lenvatinib (Schilddrüsenkarzinom) : Nutzenbewertung gemäß § 35a SGB V
Time to achieve remission determines time to be in remission
Exploiting antitumor immunity to overcome relapse and improve remission duration
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Durable clinical remission of a skull metastasis under intralesional Viscum album extract therapy : : case report
Lenvatinib beim Radiojod-refraktären differenzierten Schilddrüsenkarzinom
Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS
Optimal monetary policy with durable and non-durable goods
Lenvatinib beim inoperablen oder fortgeschrittenen hepatozellulären Karzinom